Non-Invasive Endotracheal Administration of Lipopolysaccharide to Induce Acute Lung Injury in Rodents
December 5th, 2025
In this study, a non-invasive endotracheal instillation technique is demonstrated to develop ALI in rats using a basic laryngoscope to ensure precise LPS delivery to the lungs. The LPS is instilled via an endotracheal tube using a laryngoscope. The magnitude of lung injury is evaluated at multiple time points.
The scope of our research is to develop a clinically relevant, non-invasive model of acute lung injury to improve the clinical testing. Modern lung biology research integrates advanced lung models, nano carriers and aerosol technologies to optimize and study targeted drug delivery within physiologically relevant models. To begin, weigh each animal using a calibrated balance.
Prepare the lipopolysaccharide solution by diluting the lyophilized Escherichia coli lipopolysaccharide in sterile PBS to achieve the desired concentration. After anesthetizing the rat, check the depth of anesthesia and position the animal in a semi recumbent position with its incisors suspended on a solid supporting platform. Then open the mouth of the anesthetized animal.
Gently grasp the tongue using curved blunt ended forceps and retract it in an upward and lateral direction. Then carefully insert the laryngoscope, aligning it precisely for optimal visualization of the tracheal opening. Now, draw 100 microliters of lipopolysaccharide solution into a syringe and attach it to a 16 gauge rat endotracheal tube.
Administer the lipopolysaccharide solution near the tracheal opening. Immediately after installation, gently occlude the nostrils using blunt ended forceps for two to four seconds to promote aspiration of the solution into the lungs through the trachea. Then, carefully reposition the tongue to its normal anatomical orientation following lipopolysaccharide delivery.
Transfer the animal back to its cage and closely monitor for any signs of respiratory compromise or choking for at least one minute. After performing bronchoalveolar lavage and tracheotomy, gently infused two milliliters of cold PBS into the lungs and retrieve the fluid carefully. Centrifuge the collected lavage fluid at 5, 000 G for five minutes at four degrees Celsius.
Use the supernatant to detect inflammatory markers. Collect the lungs for histopathological examination, or homogenize them for myeloperoxidase activity. Compared to the control group, the group euthanized 24 hours after lipopolysaccharide installation, showed a significant increase in interleukin-1 beta levels, elevated myeloperoxidase activity and higher total protein content.
At 120 hours post lipopolysaccharide installation, interleukin-1 beta, myeloperoxidase activity and total protein levels had returned to near baseline values. Lung histopathology at 24 hours demonstrated disintegrated alveolar structure, swelling of the alveolar wall, hemolysis, and severe neutrophil infiltration. Lung architecture was restored at 120 hours post lipopolysaccharide installation.
Using non-invasive endotracheal pulmonary delivery, we created a self-limiting acute lung injury models for testing targeted therapeutics and studying lung repair. The key benefit of this method is it's precise non-traumatic delivery, which facilitates repeated dosing in the same animal and customization for a particular research objectives. Future acute lung injury research will focus on developing targeted therapies and understanding lung injury and repair mechanism.
View the full transcript and gain access to thousands of scientific videos
Overview
This study presents a non-invasive endotracheal instillation technique to induce acute lung injury (ALI) in rats, utilizing a laryngoscope for precise lipopolysaccharide (LPS) delivery. The lung injury is assessed at various time points to evaluate the model's effectiveness.
Key Study Components
Area of Science
- Neuroscience
- Respiratory Biology
- Animal Models
Background
- Acute lung injury is a significant clinical condition requiring effective research models.
- Existing models may be invasive, limiting their utility in repeated studies.
- Non-invasive techniques can enhance the study of lung injury and repair mechanisms.
- Targeted drug delivery is crucial for therapeutic development.
Purpose of Study
- To develop a clinically relevant model of ALI using a non-invasive approach.
- To facilitate the testing of targeted therapeutics.
- To understand the mechanisms of lung injury and repair.
Methods Used
- Preparation of LPS solution and anesthetization of rats.
- Endotracheal tube insertion using a laryngoscope for LPS delivery.
- Monitoring of respiratory status post-instillation.
- Bronchoalveolar lavage and histopathological examination of lung tissue.
Main Results
- Significant increase in inflammatory markers at 24 hours post-LPS installation.
- Restoration of lung architecture observed at 120 hours post-instillation.
- Demonstrated the model's utility for studying lung repair mechanisms.
- Non-invasive delivery allows for repeated dosing and customization.
Conclusions
- The non-invasive technique effectively induces ALI in a controlled manner.
- This model can aid in the development of targeted therapies.
- Future research will focus on further understanding lung injury mechanisms.
Frequently Asked Questions
Executive Industry Relevance
Non-invasive endotracheal LPS administration in rodents provides a clinically relevant, reproducible model for acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) research. This approach enables precise, targeted delivery with minimal tissue trauma, supporting robust evaluation of inflammatory mechanisms and therapeutic interventions. The model's reliability and adaptability make it valuable for early-stage drug discovery and translational respiratory research portfolios.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of inflammatory pathways and cellular responses in ALI and ARDS.
- Supports functional target validation by quantifying cytokine and myeloperoxidase activity.
- Facilitates mechanistic de-risking by distinguishing direct pulmonary effects from systemic confounders.
- Provides a platform for hypothesis-driven evaluation of novel anti-inflammatory agents.
Screening & Assay Development
- Delivers a standardized, reproducible injury model for preclinical compound screening.
- Generates quantitative outputs such as interleukin-1 beta and total protein for assay development.
- Enables high-throughput evaluation of candidate therapeutics in a controlled lung injury context.
- Supports platform reuse for iterative testing and optimization of drug formulations.
Translational & Preclinical Research
- Aligns with disease-relevant endpoints for ALI and ARDS translational studies.
- Enables longitudinal assessment of lung repair and therapeutic efficacy.
- Facilitates integration with advanced imaging for real-time monitoring of drug distribution and disease progression.
- Supports risk-adjusted advancement of respiratory drug candidates.
Pipeline & Workflow Integration
This non-invasive rodent ALI model bridges early discovery, lead identification, and preclinical validation for respiratory therapeutics.
- Discovery Biology: Provides a robust platform for hypothesis testing and pathway clarification in lung inflammation.
- Screening: Offers reproducible, quantitative readouts for compound evaluation and assay standardization.
- Analytics: Enables measurement of inflammatory markers, protein content, and histopathological changes for comparative analysis.
- Translational Research: Supports continuity from mechanistic studies to preclinical efficacy and biomarker alignment.
- Enterprise Reuse: Adaptable for repeated dosing, longitudinal studies, and diverse research objectives in respiratory disease.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in ALI/ARDS research.
- Operational Value: Enhances standardization, reproducibility, and scalability of preclinical lung injury studies.
- Strategic Value: Improves go/no-go decision-making and capital efficiency by enabling robust target and therapeutic evaluation.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of respiratory drug candidates.
Implementation Considerations
- Requires expertise in rodent anesthesia, airway management, and endotracheal techniques.
- Needs access to laryngoscopes, endotracheal tubes, and analytical platforms for biomarker quantification.
- Demands cross-team standardization of dosing, monitoring, and sample collection protocols.
- Adaptable across rodent species and compatible with advanced imaging modalities.
- Limited to preclinical research; not directly translatable to clinical or regulatory endpoints.
